|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Coronary Heart Disease | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Coronary Disease | |||||
| Heart Diseases | |||||
| 3 | More general conditions related to this trial | ||||
| Cardiovascular Diseases | |||||
| Myocardial Ischemia | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| impact on VASP test | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Clopidogrel | |||||
| Omeprazole | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Ulcer Agents | |||||
| Enzyme Inhibitors | |||||
| Gastrointestinal Agents | |||||
| Hematologic Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Platelet Aggregation Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| University Hospital, Brest | |||||